Current Controversies, Recent Developments and Emerging Strategies in the Management of Breast Cancer: A Clinical Investigator Think TankAdjuvant T-DM1 trials
0:41 minutes.
TRANSCRIPTION:
DR KROP: So I mean, I think the data in the metastatic setting certainly would support looking in the adjuvant setting. We’ve actually completed a pilot study of 150 or so patients in the neoadjuvant and adjuvant setting to show that it’s safe to give T-DM1 after an anthracycline. That study has been completed and we’ll have that cardiac safety data relatively soon, I think probably at ASCO. And then I think there’s certainly a lot of interest in moving T-DM1 into an adjuvant study. Obviously, it’s complicated because we now know how hard it is to do adjuvant studies in HER2-positive space because the current standards are so good. |